Theravance Net Receivables vs Total Assets Analysis

TBPH Stock

USD 9.47 0.14 1.46%

Theravance Biopharma financial indicator trend analysis is much more than just breaking down Theravance Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theravance Biopharma is a good investment. Please check the relationship between Theravance Biopharma Net Receivables and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.

Net Receivables vs Total Assets

Net Receivables vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theravance Biopharma Net Receivables account and Total Assets. At this time, the significance of the direction appears to have weak relationship.

The correlation between Theravance Biopharma's Net Receivables and Total Assets is 0.38. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Assets in the same time period over historical financial statements of Theravance Biopharma, assuming nothing else is changed. The correlation between historical values of Theravance Biopharma's Net Receivables and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Theravance Biopharma are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Receivables i.e., Theravance Biopharma's Net Receivables and Total Assets go up and down completely randomly.

Correlation Coefficient

0.38

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Receivables

Total Assets

Total assets refers to the total amount of Theravance Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Theravance Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from Theravance Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theravance Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.As of now, Theravance Biopharma's Sales General And Administrative To Revenue is increasing as compared to previous years.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	293.0M	130.5M	110.7M	105.2M
Cost Of Revenue	7.3M	6.6M	40.6M	55.9M

Total Operating Expenses Cost Of Revenue

Theravance Biopharma fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Other Liab	Accounts Payable	Other Assets	Inventory	Other Current Assets	Total Liab	Property Plant Equipment	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Net Receivables	Short Term Investments	Non Current Liabilities Total	Long Term Investments	Property Plant And Equipment Gross	Short Long Term Debt
Common Stock Shares Outstanding		0.73	0.46	0.41	0.5	-0.46	0.45	-0.18	0.67	0.7	0.55	-0.14	0.13	0.82	0.04	-0.9	0.23	0.67	0.5	0.72	0.61	-0.27	0.73	-0.48	0.66	-0.85
Total Assets	0.73		0.44	0.46	0.48	-0.19	0.32	-0.08	0.49	0.56	0.15	0.28	0.42	0.42	0.07	-0.66	0.56	0.55	0.33	0.37	0.38	-0.19	0.56	-0.25	0.34	-0.56
Other Current Liab	0.46	0.44		0.87	-0.33	0.08	-0.39	0.58	0.73	0.85	0.33	-0.57	-0.33	0.47	0.28	-0.68	0.04	-0.14	-0.36	-0.11	0.73	0.44	0.83	0.0	-0.1	-0.33
Total Current Liabilities	0.41	0.46	0.87		-0.2	0.21	-0.39	0.22	0.63	0.87	0.15	-0.57	-0.39	0.43	0.66	-0.64	0.16	-0.21	-0.36	-0.05	0.65	0.43	0.83	-0.22	-0.03	-0.44
Other Liab	0.5	0.48	-0.33	-0.2		-0.45	0.92	-0.67	0.16	-0.04	-0.07	0.47	0.69	0.33	-0.14	-0.3	0.13	0.84	0.92	0.78	-0.05	-0.45	-0.02	-0.7	0.71	-0.6
Accounts Payable	-0.46	-0.19	0.08	0.21	-0.45		-0.5	0.29	-0.06	-0.13	-0.22	-0.01	-0.18	-0.41	0.19	0.28	-0.03	-0.54	-0.53	-0.7	0.05	0.0	-0.17	0.16	-0.54	0.38
Other Assets	0.45	0.32	-0.39	-0.39	0.92	-0.5		-0.58	0.14	-0.19	0.0	0.49	0.76	0.41	-0.42	-0.23	-0.08	0.92	0.99	0.75	0.02	-0.57	-0.16	-0.65	0.77	-0.53
Inventory	-0.18	-0.08	0.58	0.22	-0.67	0.29	-0.58		0.16	0.12	0.05	-0.2	-0.21	-0.21	-0.28	0.06	-0.14	-0.45	-0.59	-0.67	0.14	0.49	0.1	0.56	-0.63	0.49
Other Current Assets	0.67	0.49	0.73	0.63	0.16	-0.06	0.14	0.16		0.77	0.5	-0.44	-0.02	0.66	0.17	-0.81	0.02	0.28	0.13	0.35	0.72	-0.08	0.77	-0.45	0.3	-0.73
Total Liab	0.7	0.56	0.85	0.87	-0.04	-0.13	-0.19	0.12	0.77		0.56	-0.64	-0.41	0.64	0.49	-0.89	0.17	0.07	-0.15	0.32	0.76	0.22	1.0	-0.21	0.26	-0.67
Property Plant Equipment	0.55	0.15	0.33	0.15	-0.07	-0.22	0.0	0.05	0.5	0.56		-0.51	-0.42	0.5	-0.11	-0.66	-0.14	0.23	0.01	0.45	0.58	-0.27	0.6	0.09	0.43	-0.47
Total Stockholder Equity	-0.14	0.28	-0.57	-0.57	0.47	-0.01	0.49	-0.2	-0.44	-0.64	-0.51		0.85	-0.36	-0.5	0.42	0.33	0.41	0.46	-0.04	-0.53	-0.42	-0.64	0.02	0.0	0.27
Net Tangible Assets	0.13	0.42	-0.33	-0.39	0.69	-0.18	0.76	-0.21	-0.02	-0.41	-0.42	0.85		0.03	-0.53	0.1	0.16	0.69	0.73	0.22	-0.2	-0.44	-0.4	-0.34	0.28	-0.11
Property Plant And Equipment Net	0.82	0.42	0.47	0.43	0.33	-0.41	0.41	-0.21	0.66	0.64	0.5	-0.36	0.03		0.04	-0.82	-0.18	0.58	0.44	0.64	0.79	-0.19	0.65	-0.59	0.76	-0.85
Current Deferred Revenue	0.04	0.07	0.28	0.66	-0.14	0.19	-0.42	-0.28	0.17	0.49	-0.11	-0.5	-0.53	0.04		-0.17	0.35	-0.45	-0.38	-0.02	0.09	0.32	0.45	-0.25	-0.16	-0.27
Retained Earnings	-0.9	-0.66	-0.68	-0.64	-0.3	0.28	-0.23	0.06	-0.81	-0.89	-0.66	0.42	0.1	-0.82	-0.17		-0.04	-0.48	-0.26	-0.6	-0.82	0.08	-0.91	0.41	-0.6	0.85
Cash	0.23	0.56	0.04	0.16	0.13	-0.03	-0.08	-0.14	0.02	0.17	-0.14	0.33	0.16	-0.18	0.35	-0.04		0.03	-0.01	0.03	-0.22	-0.25	0.17	0.13	-0.24	-0.08
Non Current Assets Total	0.67	0.55	-0.14	-0.21	0.84	-0.54	0.92	-0.45	0.28	0.07	0.23	0.41	0.69	0.58	-0.45	-0.48	0.03		0.93	0.79	0.27	-0.59	0.11	-0.51	0.83	-0.64
Non Currrent Assets Other	0.5	0.33	-0.36	-0.36	0.92	-0.53	0.99	-0.59	0.13	-0.15	0.01	0.46	0.73	0.44	-0.38	-0.26	-0.01	0.93		0.78	0.04	-0.58	-0.11	-0.64	0.76	-0.55
Long Term Debt	0.72	0.37	-0.11	-0.05	0.78	-0.7	0.75	-0.67	0.35	0.32	0.45	-0.04	0.22	0.64	-0.02	-0.6	0.03	0.79	0.78		0.26	-0.43	0.36	-0.59	0.88	-0.82
Net Receivables	0.61	0.38	0.73	0.65	-0.05	0.05	0.02	0.14	0.72	0.76	0.58	-0.53	-0.2	0.79	0.09	-0.82	-0.22	0.27	0.04	0.26		-0.05	0.75	-0.28	0.44	-0.63
Short Term Investments	-0.27	-0.19	0.44	0.43	-0.45	0.0	-0.57	0.49	-0.08	0.22	-0.27	-0.42	-0.44	-0.19	0.32	0.08	-0.25	-0.59	-0.58	-0.43	-0.05		0.18	0.21	-0.43	0.33
Non Current Liabilities Total	0.73	0.56	0.83	0.83	-0.02	-0.17	-0.16	0.1	0.77	1.0	0.6	-0.64	-0.4	0.65	0.45	-0.91	0.17	0.11	-0.11	0.36	0.75	0.18		-0.2	0.29	-0.69
Long Term Investments	-0.48	-0.25	0.0	-0.22	-0.7	0.16	-0.65	0.56	-0.45	-0.21	0.09	0.02	-0.34	-0.59	-0.25	0.41	0.13	-0.51	-0.64	-0.59	-0.28	0.21	-0.2		-0.62	0.74
Property Plant And Equipment Gross	0.66	0.34	-0.1	-0.03	0.71	-0.54	0.77	-0.63	0.3	0.26	0.43	0.0	0.28	0.76	-0.16	-0.6	-0.24	0.83	0.76	0.88	0.44	-0.43	0.29	-0.62		-0.79
Short Long Term Debt	-0.85	-0.56	-0.33	-0.44	-0.6	0.38	-0.53	0.49	-0.73	-0.67	-0.47	0.27	-0.11	-0.85	-0.27	0.85	-0.08	-0.64	-0.55	-0.82	-0.63	0.33	-0.69	0.74	-0.79

Click cells to compare fundamentals

Theravance Biopharma Account Relationship Matchups

Theravance Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	55.6M	62.3M	69.5M	73.6M	55.3M	53.3M
Total Assets	408.8M	469.1M	374.8M	607.4M	382.0M	418.6M
Other Current Liab	57.8M	116.9M	63.1M	20.4M	15.4M	14.6M
Total Current Liabilities	111.7M	123.6M	58.6M	28.7M	24.8M	23.5M
Other Liab	28.0M	2.2M	2.7M	91.5M	105.2M	110.5M
Accounts Payable	4.8M	6.8M	3.1M	1.6M	1.5M	1.4M
Other Assets	6.1M	3.3M	4.1M	201.9M	232.2M	243.8M
Inventory	0.0	1.0	20.4M	10.2M	1.5M	0.95
Other Current Assets	7.1M	30.7M	18.8M	9.2M	13.6M	11.4M
Total Liab	632.7M	772.8M	713.4M	165.6M	169.0M	160.6M
Property Plant Equipment	12.6M	16.4M	53.3M	11.9M	13.7M	16.5M
Total Stockholder Equity	(223.8M)	(303.8M)	(338.6M)	441.8M	213.0M	223.6M
Net Tangible Assets	(169.4M)	116.7M	(338.6M)	577.0M	519.3M	545.3M
Property Plant And Equipment Net	59.2M	59.7M	53.3M	52.0M	45.4M	33.1M
Current Deferred Revenue	31.6M	11.5M	98K	24K	(5.4M)	(5.2M)
Retained Earnings	(1.2B)	(1.5B)	(1.7B)	(853.9M)	(909.1M)	(954.6M)
Cash	58.1M	81.5M	90.0M	298.2M	39.5M	37.6M
Non Current Assets Total	70.3M	75.7M	124.9M	253.9M	248.5M	260.9M
Non Currrent Assets Other	6.1M	3.3M	4.1M	201.1M	203.1M	213.3M
Long Term Debt	454.4M	445.2M	227.0M	599.4M	689.3M	723.8M
Net Receivables	50.6M	69.7M	57.6M	16.8M	17.5M	27.9M
Short Term Investments	222.8M	211.5M	83.5M	29.3M	62.9M	112.2M
Liabilities And Stockholders Equity	408.8M	469.1M	374.8M	607.4M	382.0M	454.6M
Non Current Liabilities Total	521.0M	649.2M	654.8M	136.9M	144.2M	137.0M
Long Term Investments	49.8M	11.9M	8.7M	12.8M	67.5M	0.0
Property Plant And Equipment Gross	59.2M	16.4M	53.3M	52.0M	66.9M	70.3M
Total Current Assets	338.5M	393.3M	249.9M	353.5M	133.5M	126.9M
Accumulated Other Comprehensive Income	145K	47K	0.0	(15K)	(65K)	(68.3K)
Net Debt	434.9M	565.6M	562.1M	(224.1M)	9.6M	9.1M
Cash And Short Term Investments	280.8M	292.9M	173.5M	327.5M	102.4M	97.3M
Retained Earnings Total Equity	(1.2B)	(1.5B)	(1.7B)	(853.9M)	(768.5M)	(806.9M)
Capital Surpluse	1.0B	1.2B	1.4B	1.3B	1.5B	1.1B
Other Stockholder Equity	1.0B	1.2B	1.4B	1.3B	1.1B	1.1B
Non Current Liabilities Other	21.3M	1.8M	2.7M	1.7M	33.7M	35.4M
Short Long Term Debt Total	492.9M	647.1M	652.1M	74.1M	49.2M	46.7M
Long Term Debt Total	454.4M	445.2M	227.0M	228.0M	262.2M	330.2M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:

How To Invest In Theravance

Details

Is Theravance Stock a good investment?

Details

What is Theravance Biopharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.03)

Revenue Per Share

1.293

Quarterly Revenue Growth

0.075

Return On Assets

(0.06)

Return On Equity

(0.23)

The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Theravance Net Receivables vs Total Assets Analysis

Net Receivables vs Total Assets

Net Receivables vs Total Assets Correlation Analysis

Correlation Coefficient

Net Receivables

Total Assets

Theravance Biopharma fundamental ratios Correlations

Theravance Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Theravance Biopharma fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Non Currrent Assets Other	+ 0.99	Other Assets
Non Currrent Assets Other	+ 0.93	Non Current Assets Total
Other Assets	+ 0.92	Other Liab
Non Currrent Assets Other	+ 0.92	Other Liab
Non Current Assets Total	+ 0.92	Other Assets

Non Current Liabilities Total	- 0.91	Retained Earnings
Retained Earnings	- 0.9	Common Stock Shares Outstanding
Retained Earnings	- 0.89	Total Liab
Short Long Term Debt	- 0.85	Property Plant And Equipment Net
Short Long Term Debt	- 0.85	Common Stock Shares Outstanding
Short Long Term Debt	- 0.82	Long Term Debt